Alpha-9 Oncology Doses First Patient in Phase 1 Clinical Trial Evaluating GRPR-Targeted Radiotherapeutics Across Multiple Solid Tumors
Cardurion Pharmaceuticals Announces Late-Breaking Presentation of Phase 2 Results for Tovinontrine (CRD-750), a PDE9 Inhibitor, in Heart Failure
TRexBio Announces Positive Topline Results from First-in-Human Phase 1a Study of TRB-061, a TNFR2 Agonist in Clinical Development for Atopic Dermatitis
Phanes Therapeutics receives FDA Fast Track designation for spevatamig in advanced and metastatic biliary tract carcinoma
Phanes Therapeutics announces expansion of clinical trial collaboration and supply agreement with Merck to evaluate spevatamig in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for treatment of biliary tract cancer
Imperative Care Launches Ikon 24 Pro Guidewire, Enhancing the Zoom Stroke System to Support More Efficient Stroke Procedures
TRexBio Announces Pipeline Progress, Naming TRB-071 as a CD30 Agonist for Immune-Mediated Diseases and Advancement of Lilly-Partnered TRB-051
Sirius Therapeutics Announces First Patient Dosed in Phase 1/2a Trial of SRSD384, a Novel INHBE-Targeting siRNA for Obesity
Rejoni, Inc. Secures $25 Million in Financing to Accelerate the Juveena® Hydrogel System Toward FDA Approval and Launch
